In vitro studies of the mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity by ferrous iron under anaerobic conditions.
Human porphyria cutanea tarda (PCT) is an unusual consequence of common hepatic disorders such as alcoholic liver disease and iron overload, where hepatic iron plays a key role in the expression of the metabolic lesion, i.e., defective hepatic decarboxylation of porphyrinogens. In this investigation, kinetic studies on a partially purified rat liver uroporphyrinogen decarboxylase have been conducted under controlled conditions to determine how iron perturbs porphyrinogen decarboxylation in vitro. The enzyme, assayed strictly under anaerobic conditions in the dark, was inhibited progressively by ferrous iron. Approximately 0.45 mM ferrous ammonium sulfate was required to observe about 50% inhibition of enzyme activity measured with uroporphyrinogen I as substrate. We showed that (a) all the steps of enzymatic decarboxylation (octa-, hepta-, hexa-, and pentacarboxylic porphyrinogen of isomer I series) were inhibited by ferrous iron. The inhibition was competitive with respect to uroporphyrinogen I and III substrates; (b) the cations, e.g., Fe3+ and Mg2+, had no effect, whereas sulfhydryl group specific cations and compounds such as Hg2+, Zn2+, p-mercuribenzoate, and 5,5'-dithiobis(2-nitrobenzoate) all inhibited the enzyme; (c) the enzyme could be protected from inhibition by Fe2+ and p-mercuribenzoate by preincubation with pentacarboxylic porphyrinogen, a natural substrate and competitive inhibitor. These data suggest for the first time a direct interaction of ferrous iron with cysteinyl residue(s) located at the active site(s) of the enzyme.
D000693:Anaerobiosis; D000818:Animals; D002021:Buffers; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003653:Decarboxylation; D005296:Ferrous Compounds / Q000494:pharmacology*; D066298:In Vitro Techniques; D007501:Iron / Q000494:pharmacology*; D007700:Kinetics; D008099:Liver / Q000201:enzymology*; D008274:Magnesium / Q000494:pharmacology; D008297:Male; D008626:Mercuribenzoates / Q000494:pharmacology; D011164:Porphyrias / Q000201:enzymology; D011165:Porphyrinogens / Q000494:pharmacology; D051381:Rats; D012871:Skin Diseases / Q000201:enzymology; D013439:Sulfhydryl Reagents / Q000494:pharmacology; D014575:Uroporphyrinogen Decarboxylase / Q000037:antagonists & inhibitors*; D014577:Uroporphyrinogens / Q000378:metabolism
C043407:4-mercuribenzoate; D002021:Buffers; D005296:Ferrous Compounds; D008626:Mercuribenzoates; D011165:Porphyrinogens; D013439:Sulfhydryl Reagents; D014577:Uroporphyrinogens; C041927:pentacarboxylic porphyrinogen; D007501:Iron; D002262:Carboxy-Lyases; D014575:Uroporphyrinogen Decarboxylase; D008274:Magnesium